Xspray Pharma: Lawsuit avoided for XS003 - Redeye

Redeye notes that it now appears beyond all reasonable doubt that Novartis will not initiate any litigation process against XS003, representing a positive development for Xspray. The next key milestone remains the PDUFA date, currently on schedule for mid-June 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1144033/xspray-pharma-no-xs003-lawsuit-seems-to-be-the-case?utm_source=finwire&utm_medium=RSS